Treatment of Non-Muscle-Invasive Bladder Cancer in the Intermediate-Risk Group Without Carcinoma In Situ
Not every case of non-muscle-invasive bladder cancer (NMIBC) falls neatly into low-risk or high-risk categories. The intermediate-risk group occupies a distinct clinical space that calls for its own structured approach.
Clinical scenario
This protocol applies to patients with non-muscle-invasive bladder cancer in the intermediate-risk group — specifically those without concurrent carcinoma in situ (CIS) whose disease does not meet the defining criteria for low-risk, high-risk, or very high-risk classification.
Treatment approach
Management in this setting centres on transurethral resection of the bladder tumour followed by intravesical instillation therapy. The protocol addresses both chemotherapy-based and BCG-based options, each with defined induction and maintenance structures. The complete sequence, schedules, and selection criteria are specified in the full regimen.
Treatment goal
The primary clinical objective is no tumour recurrence on cystoscopy at 3 months — an early indicator that is also a key prognostic marker for longer-term outcomes.